Flares in autoimmune rheumatic diseases in the post-COVID-19 vaccination period - A Cross-sequential study based on COVAD surveys.
Kshitij JagtapNaveen RJessica A DayParikshit SenBinit VaidyaAlbert Selva-O'CallaghanElena NikiphorouAi Lyn TanVishwesh AgarwalSreoshy SahaSamuel Katsuyuki ShinjoNelly ZiadéMasataka KuwanaTsvetelina V VelikovaMarcin MilchertIoannis ParodisAbraham Edgar Gracia-RamosLorenzo CavagnaMasataka KuwanaJohannes KnitzaAshima MakolAarat PatelJohn D PaulingChris WincupBhupen BarmanErick Adrian Zamora TehozolJorge Rojas SerranoIgnacio García-De La TorreIris Jazmin Colunga-PedrazaFrancisco Javier Merayo-ChalicoCelestine Chibuzo OkwaraWanrachada KatchamartPhonpen Akawatcharangura GooRusska ShumnalievaYi Ming ChenLeonardo Santos HoffEl Lina KibbiHussein HalabiSyahrul Sazliyana ShaharirA T M Tanveer HasanDzifa DeyCarlos Enrique Toro GutiérrezCarlo V Caballero UribeJames B LillekerBabur SalimTamer A GheitaTulika ChatterjeeMiguel Ángel Saavedra-SalinasOliver Distlernull nullGabriela Arredondo Hector ChinoyVikas AgarwalRohit AggarwalLatika GuptaPublished in: Rheumatology (Oxford, England) (2023)
Flares occur in nearly one in ten individuals with AIRDs after COVID vaccination, with people with comorbidities, especially AID multimorbidity, mental health disorders and use of the Moderna vaccine being particularly vulnerable. Future avenues include exploring flare profiles and optimizing vaccine strategies for this group.